Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

NCT01916993 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

Interventions

DRUG: NBI-98854 50 mg capsule

Sponsor

Neurocrine Biosciences